Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights Meeting Abstract
| Authors: | Keane, F.; Tuli, R.; O'Connor, C. A.; Schwartz, C.; Park, W.; Varghese, A. M.; Perry, M.; Singhal, A.; Vardhana, S.; Hendifar, A. E.; Tarcan, Z.; Basturk, O.; McDermott, R. S.; Reyngold, M.; Crane, C. H.; O'Reilly, E. M.; Schoenfeld, J. D. |
| Abstract Title: | Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401142 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.4174 |
| Notes: | Meeting Abstract: 4174 -- Source: Wos |
